File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Differential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma

TitleDifferential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinoma
Authors
KeywordsGleason score
Metastasis
MSX2
Preoperative serum PSA
Prostate cancer
Issue Date2010
PublisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APMIS
Citation
APMIS, 2010, v. 118 n. 12, p. 918-926 How to Cite?
AbstractOne of the common features in advanced prostate cancer is bone metastasis. In this study, we investigated the clinical relevance of a bone factor, MSX2, in predicting the metastatic ability of prostate adenocarcinoma. Evaluation of MSX2 expression was performed using prostate cell lines as well as patient specimens. A sharp decrease in MSX2 was found in primary prostate cancer cells, 22Rv1, when compared with the non-malignant counterparts, followed by a gradual increase in more aggressive prostate cancer cell lines. Interestingly, the MSX2 protein was upregulated and predominantly expressed in the nucleus in aggressive prostate cancer cell line, C4-2b, compared with the less aggressive 22Rv1. Consistent with the in vitro results, MSX2 nuclear expression was significantly higher in nodular hyperplasia when compared with high-grade prostatic intraepithelial neoplasia (PIN), while MSX2 nuclear expression in prostate adenocarcinoma was higher than that in high-grade PIN. Importantly, MSX2 expression was increased significantly in tumors with metastasis compared with those without metastasis. Finally, MSX2 nuclear scores were significantly increased in patients with preoperative serum PSA >20 ng/mL. No correlation between MSX2 nuclear score and Gleason score was found. Taken together, MSX2 may serve as a potential biomarker in predicting primary prostate tumors with higher metastatic capability. © 2010 The Authors. Journal Compilation © 2010 APMIS.
Persistent Identifierhttp://hdl.handle.net/10722/139938
ISSN
2015 Impact Factor: 1.933
2015 SCImago Journal Rankings: 0.855
ISI Accession Number ID
Funding AgencyGrant Number
RGCHKU7490/03M
HKU7470/04M
HKU Foundation
NSFC/RGC
NHKU738/03
Funding Information:

This work was supported by RGC grants to Y. C. Wong (HKU7490/03M, HKU7470/04M, HKU Foundation Seed Funding/03, NSFC/RGC, NHKU 738/03).

References

 

DC FieldValueLanguage
dc.contributor.authorChua, CWen_HK
dc.contributor.authorChiu, YTen_HK
dc.contributor.authorYuen, HFen_HK
dc.contributor.authorChan, KWen_HK
dc.contributor.authorWang, Xen_HK
dc.contributor.authorLing, MTen_HK
dc.contributor.authorWong, YCen_HK
dc.date.accessioned2011-09-23T06:02:06Z-
dc.date.available2011-09-23T06:02:06Z-
dc.date.issued2010en_HK
dc.identifier.citationAPMIS, 2010, v. 118 n. 12, p. 918-926en_HK
dc.identifier.issn0903-4641en_HK
dc.identifier.urihttp://hdl.handle.net/10722/139938-
dc.description.abstractOne of the common features in advanced prostate cancer is bone metastasis. In this study, we investigated the clinical relevance of a bone factor, MSX2, in predicting the metastatic ability of prostate adenocarcinoma. Evaluation of MSX2 expression was performed using prostate cell lines as well as patient specimens. A sharp decrease in MSX2 was found in primary prostate cancer cells, 22Rv1, when compared with the non-malignant counterparts, followed by a gradual increase in more aggressive prostate cancer cell lines. Interestingly, the MSX2 protein was upregulated and predominantly expressed in the nucleus in aggressive prostate cancer cell line, C4-2b, compared with the less aggressive 22Rv1. Consistent with the in vitro results, MSX2 nuclear expression was significantly higher in nodular hyperplasia when compared with high-grade prostatic intraepithelial neoplasia (PIN), while MSX2 nuclear expression in prostate adenocarcinoma was higher than that in high-grade PIN. Importantly, MSX2 expression was increased significantly in tumors with metastasis compared with those without metastasis. Finally, MSX2 nuclear scores were significantly increased in patients with preoperative serum PSA >20 ng/mL. No correlation between MSX2 nuclear score and Gleason score was found. Taken together, MSX2 may serve as a potential biomarker in predicting primary prostate tumors with higher metastatic capability. © 2010 The Authors. Journal Compilation © 2010 APMIS.en_HK
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing, Inc. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APMISen_HK
dc.relation.ispartofAPMISen_HK
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectGleason scoreen_HK
dc.subjectMetastasisen_HK
dc.subjectMSX2en_HK
dc.subjectPreoperative serum PSAen_HK
dc.subjectProstate canceren_HK
dc.subject.meshAdenocarcinoma - metabolism-
dc.subject.meshHomeodomain Proteins - biosynthesis - metabolism-
dc.subject.meshProstatic Hyperplasia - metabolism-
dc.subject.meshProstatic Intraepithelial Neoplasia - metabolism-
dc.subject.meshProstatic Neoplasms - metabolism-
dc.titleDifferential expression of MSX2 in nodular hyperplasia, high-grade prostatic intraepithelial neoplasia and prostate adenocarcinomaen_HK
dc.typeArticleen_HK
dc.identifier.emailChan, KW:hrmtckw@hku.hken_HK
dc.identifier.emailLing, MT:patling@hkucc.hku.hken_HK
dc.identifier.emailWong, YC:ycwong@hkucc.hku.hken_HK
dc.identifier.authorityChan, KW=rp00330en_HK
dc.identifier.authorityLing, MT=rp00449en_HK
dc.identifier.authorityWong, YC=rp00316en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1600-0463.2010.02626.xen_HK
dc.identifier.pmid21091772-
dc.identifier.scopuseid_2-s2.0-78649516698en_HK
dc.identifier.hkuros192494en_US
dc.identifier.hkuros218577-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-78649516698&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume118en_HK
dc.identifier.issue12en_HK
dc.identifier.spage918en_HK
dc.identifier.epage926en_HK
dc.identifier.isiWOS:000284317500002-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChua, CW=9437494600en_HK
dc.identifier.scopusauthoridChiu, YT=23975797700en_HK
dc.identifier.scopusauthoridYuen, HF=14018633400en_HK
dc.identifier.scopusauthoridChan, KW=16444133100en_HK
dc.identifier.scopusauthoridWang, X=37027634500en_HK
dc.identifier.scopusauthoridLing, MT=7102229780en_HK
dc.identifier.scopusauthoridWong, YC=7403041798en_HK
dc.identifier.citeulike8374405-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats